Can I read Cecropin A-Derived Peptide for the Treatment of Osteomyelitis by Inhibiting the Growth of Multidrug-Resistant Bacteria and Eliminating Inflammation on EtoBox?

Cecropin A-Derived Peptide for the Treatment of Osteomyelitis by Inhibiting the Growth of Multidrug-Resistant Bacteria and Eliminating Inflammation by Ziao Zhou, Peng Zhang, Dinghao Chen, Nan Kong, Huayang Liu, Juan Liang, Kai Huang & Huaimin Wang is a book available to read on EtoBox.

What is Cecropin A-Derived Peptide for the Treatment of Osteomyelitis by Inhibiting the Growth of Multidrug-Resistant Bacteria and Eliminating Inflammation about?

ABSTRACT: Osteomyelitis poses substantial therapeutic challenges dueto the prevalence of multidrug-resistant bacterial infections andassociated inflammation. Current treatment regimens often rely on acombination of corticosteroids and antibiotics, which can lead tocomplications and impede effective bacterial clearance. In this study,we present CADP-10, a Cecropin A-derived peptide, designed to targetmethicillin-resistant Staphylococcus aureus (MRSA) and multidrugresistant Escherichia coli (MRE), while simultaneously addressinginflammatory responses. CADP-10 self-assembles into nanobacterial net(NBacN) that selectively identify and bind to bacterial endotoxins (LPSand LTA), disrupting membrane integrity and depolarizing membranepotential, which culminates in bacterial death. Importantly, these NBacNare bound to LPS and LTA from dead bacteria, preventing theirengagement with TLR receptors and effectively blocking downstream inflammatory pathways. Our assessments of CADP-10demonstrate good biosafety in both in vitro and in vivo models. Notably, in a rabbit osteomyelitis model, CADP-10 eliminatedMRSA-induced bone infections, mitigated inflammation, and promoted bone tissue regeneratio

Author

Ziao Zhou, Peng Zhang, Dinghao Chen, Nan Kong, Huayang Liu, Juan Liang, Kai Huang & Huaimin Wang

Published

2025

Language

EN